News | March 01, 2024
Briefs: Eugia Pharma Specialities and Eugia SEZ
Eugia Pharma Specialities restarts production at terminally sterilized product lines
Eugia Pharma Specialities restarts production at terminally sterilized product lines
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
_in_Mizushima,_Japan_256_384.jpg)
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
The facility will accommodate over 1,500 employees
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Varenicline is indicated for smoking cessation in adults
Leishmaniasis is caused by protozoan parasites which are transmitted by the bite of infected female phlebotomine sandflies
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
_Rupak_Singla_256_384.jpg)
Experts discussed the latest innovations, challenges, & collaborative solutions in the fight against TB at NHWIC-2024 held at AIIMS, Delhi
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Subscribe To Our Newsletter & Stay Updated
